Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core

Neuroscience Letters

Volumn 505, Issue 2, 2011, Pages 109-112

  Sullivan, Christopher P ^a,b   Berg, Eric A ^c   Elliott Bryant, Rosemary ^a   Fishman, Jordan B ^c   McKee, Ann C ^a,b   Morin, Peter J ^a,b   Shia, Michael A ^c   Fine, Richard E ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c 21st Century Biochemicals Inc   (United States)

Author keywords

A pyroglutamate 11; A pyroglutamate 3; Alzheimer's disease; Colocalization; Senile plaques; Specific antibodies

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN PYROGLUTAMIC ACID 11; AMYLOID BETA PROTEIN PYROGLUTAMIC ACID 3; POLYCLONAL ANTIBODY; PYROGLUTAMIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONFOCAL MICROSCOPY; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; SENILE PLAQUE; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CEREBRAL CORTEX; HUMANS; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; PYRROLIDONECARBOXYLIC ACID;

EID: 81055155827     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.09.071     Document Type: Article

References (22)

1. Cynis H., Scheel E., Saido T.C., Schilling S., Demuth H.U. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry 2008, 47:7405-7413.
2. D'Arrigo C., Tabaton M., Perico A. N-terminal truncated pyroglutamyl beta amyloid peptide Abetapy3-42 shows a faster aggregation kinetics than the full-length Abeta1-42. Biopolymers 2009, 91:861-873.
3. Gunn A.P., Masters C.L., Cherny R.A. Pyroglutamate-Abeta: role in the natural history of Alzheimer's disease. Int. J. Biochem. Cell Biol. 2010, 42:1915-1918.
4. Hartlage-Rubsamen M., Morawski M., Waniek A., Jager C., Zeitschel U., Koch B., Cynis H., Schilling S., Schliebs R., Demuth H.U., Rossner S. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Abeta deposits in hippocampus via distinct cellular mechanisms. Acta Neuropathol. 2011, 121:705-719.
5. Jawhar S., Wirths O., Schilling S., Graubner S., Demuth H.U., Bayer T.A. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J. Biol. Chem. 2010, 286:4454-4460.
6. Liu K., Doms R.W., Lee V.M. Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. Biochemistry 2002, 41:3128-3136.
7. Liu K., Solano I., Mann D., Lemere C., Mercken M., Trojanowski J.Q., Lee V.M. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. Acta Neuropathol. 2006, 112:163-174.
8. Morawski M., Hartlage-Rubsamen M., Jager C., Waniek A., Schilling S., Schwab C., McGeer P.L., Arendt T., Demuth H.U., Rossner S. Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease. Acta Neuropathol. 2010, 120:195-207.
9. Mori H., Takio K., Ogawara M., Selkoe D.J. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J. Biol. Chem. 1992, 267:17082-17086.
10. Mrak R.E., Griffin W.S. Trisomy 21 and the brain. J. Neuropathol. Exp. Neurol. 2004, 63:679-685.
11. Murphy M.P., LeVine H. Alzheimer's disease and the amyloid-beta peptide. J. Alzheimers Dis. 2010, 19:311-323.
12. Perez-Garmendia R., Ibarra-Bracamontes V., Vasilevko V., Luna-Munoz J., Mena R., Govezensky T., Acero G., Manoutcharian K., Cribbs D.H., Gevorkian G. Anti-11[E]-pyroglutamate-modified amyloid beta antibodies cross-react with other pathological Abeta species: relevance for immunotherapy. J. Neuroimmunol. 2010, 229:248-255.
13. Piccini A., Russo C., Gliozzi A., Relini A., Vitali A., Borghi R., Giliberto L., Armirotti A., D'Arrigo C., Bachi A., Cattaneo A., Canale C., Torrassa S., Saido T.C., Markesbery W., Gambetti P., Tabaton M. beta-Amyloid is different in normal aging and in Alzheimer disease. J. Biol. Chem. 2005, 280:34186-34192.
14. Pike C.J., Overman M.J., Cotman C.W. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J. Biol. Chem. 1995, 270:23895-23898.
15. Saido T.C., Iwatsubo T., Mann D.M., Shimada H., Ihara Y., Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995, 14:457-466.
16. Schilling S., Lauber T., Schaupp M., Manhart S., Scheel E., Bohm G., Demuth H.U. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 2006, 45:12393-12399.
17. Schilling S., Zeitschel U., Hoffmann T., Heiser U., Francke M., Kehlen A., Holzer M., Hutter-Paier B., Prokesch M., Windisch M., Jagla W., Schlenzig D., Lindner C., Rudolph T., Reuter G., Cynis H., Montag D., Demuth H.U., Rossner S. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat. Med. 2008, 14:1106-1111.
18. Seifert F., Schulz K., Koch B., Manhart S., Demuth H.U., Schilling S. Glutaminyl cyclases display significant catalytic proficiency for glutamyl substrates. Biochemistry 2009, 48:11831-11833.
19. Sevalle J., Amoyel A., Robert P., Fournie-Zaluski M.C., Roques B., Checler F. Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J. Neurochem. 2009, 109:248-256.
20. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
21. Wirths O., Bethge T., Marcello A., Harmeier A., Jawhar S., Lucassen P.J., Multhaup G., Brody D.L., Esparza T., Ingelsson M., Kalimo H., Lannfelt L., Bayer T.A. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J. Neural Transm. 2010, 117:85-96.
22. Wirths O., Erck C., Martens H., Harmeier A., Geumann C., Jawhar S., Kumar S., Multhaup G., Walter J., Ingelsson M., Degerman-Gunnarsson M., Kalimo H., Huitinga I., Lannfelt L., Bayer T.A. Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J. Biol. Chem. 2010, 285:41517-41524.